What happened with PRCT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
PROCEPT BioRobotics Corporation supplies hospitals with AquaBeam and HYDROS Robotic Systems. These systems let surgeons plan treatment using real-time imaging, then use a robot-controlled, heat-free waterjet to remove prostate tissue. The procedure, called Aquablation therapy, treats benign prostate enlargement.
Hospitals buy or lease the systems and purchase a single-use handpiece for each procedure. Handpieces and other consumables generate most revenue, with system sales and rentals contributing the next-largest share. Most revenue comes from the United States, where the company sells primarily through its own sales team.
The business depends on hospitals adopting the systems and surgeons using them for procedures. Medicare and private insurers reimburse healthcare providers rather than PROCEPT directly, but their coverage and payment levels influence demand and what hospitals can pay for its products. New intended uses and significant product changes generally require FDA authorization, and the company cannot promote uses outside those cleared or approved.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Boston Scientific's laser therapies and Rezum compete for urologists' treatment choices with PROCEPT's Aquablation systems, which it sells mainly to U.S. hospitals to treat enlarged prostates. Watch news about those treatments rather than Boston Scientific's broader medical-device business for signs of pressure on Aquablation adoption.
Teleflex's UroLift treats enlarged prostates without removing tissue, competing for patients and urologists with PROCEPT's tissue-removing Aquablation systems. Teleflex supplies medical devices to hospitals and healthcare providers across many procedures, so UroLift news is more relevant to PROCEPT than its overall results.
Profound Medical and PROCEPT both depend on adoption of image-guided prostate treatment equipment and procedures that use a disposable device for each patient: Profound sells MRI-guided TULSA-PRO ultrasound equipment, while PROCEPT sells Aquablation robotic systems mainly to U.S. hospitals. Watch Profound's single-use device revenue for a related signal of procedure growth—the same equipment-and-consumables model behind PROCEPT's handpiece revenue.
Boston Scientific Corp. earningsBSX
Boston Scientific's report can show whether its laser therapies and Rezum are drawing patients and urologists toward alternatives to PROCEPT's Aquablation treatment for enlarged prostates.
Look for Boston Scientific's comments on demand for or use of its laser therapies and Rezum; its overall medical-device results are not a signal about prostate treatment choices. Stronger demand or use would mean more patients and urologists are choosing treatments that compete with Aquablation, making hospital adoption and procedure use harder for PROCEPT to win. Weaker traction would mean less evidence of that pressure, but would not prove hospitals are turning to PROCEPT instead.
PROCEPT BioRobotics Corporation earningsThis company
PROCEPT's report will show whether hospitals are still buying its robotic systems and whether sales of the single-use handpieces are growing alongside them.
Read system sales and rentals alongside revenue from handpieces and other single-use consumables, then check gross margin—the share of revenue left after product manufacturing costs. If both revenue streams grow and gross margin holds or rises, hospital purchases are translating into ongoing use and higher production is helping spread manufacturing costs. If systems grow but consumables lag, or gross margin falls, placements may not be driving use at the same pace, or costs and pricing pressure may be eating into the business.
Profound Medical Corp. earningsPROF
Profound Medical's report will show how sales of single-use devices tied to its MRI-guided prostate-treatment equipment are faring, an indirect read-through for the equipment-and-consumables model behind PROCEPT's handpieces.
Focus on Profound Medical's single-use device revenue and whether the company links any change to procedure volume or equipment use. If revenue rises alongside more procedures or use, that supports demand for consumables tied to image-guided treatment equipment—a relevant but not equivalent signal for ongoing use of PROCEPT's handpieces. If revenue or use weakens, the signal for that model is less supportive, though the companies' treatments and products are different.
